information. Any person that is neither a party to the five-year review nor an interested party may submit a brief written statement (which shall not contain any new factual information) pertinent to the review by August 8, 2017. However, should the Department of Commerce extend the time limit for its completion of the final results of its review, the deadline for comments (which may not contain new factual information) on Commerce’s final results is three business days after the issuance of Commerce’s results. If comments contain business proprietary information (BPI), they must conform with the requirements of sections 201.6, 207.3, and 207.7 of the Commission’s rules. The Commission’s rules with respect to filing were revised effective July 25, 2014. See 79 FR 35920 (June 25, 2014), and the revised Commission Handbook on E-filing, available from the Commission’s Web site at https://edis.usitc.gov.

In accordance with sections 201.16(c) and 207.3 of the rules, each document filed by a party to the review must be served on all other parties to the review (as identified by either the public or BPI service list), and a certificate of service must be timely filed. The Secretary will not accept a document for filing without a certificate of service.

Determination.—The Commission has determined this review is extraordinarily complicated and therefore has determined to exercise its authority to extend the review period by up to 90 days pursuant to 19 U.S.C. 1675(c)(5)(B).

Authority: This review is being conducted under authority of title VII of the Tariff Act of 1930; this notice is published pursuant to section 207.62 of the Commission’s rules.

By order of the Commission.


Lisa R. Barton,
Secretary to the Commission.

[FR Doc. 2017–16677 Filed 8–7–17; 8:45 am]

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–392]

Importer of Controlled Substances Registration

ACTION: Notice of registration.

SUMMARY: Registrants listed below have applied for and been granted registration by the Drug Enforcement Administration (DEA) as importers of various classes of schedule I or II controlled substances.

SUPPLEMENTARY INFORMATION: The companies listed below applied to be registered as importers of various basic classes of controlled substances. Information on previously published notices is listed in the table below. No comments or objections were submitted and no requests for hearing were submitted for these notices.

<table>
<thead>
<tr>
<th>Company</th>
<th>FR docket</th>
<th>Published</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cambridge Isotope Laboratories</td>
<td>82 FR 19083</td>
<td>April 25, 2017.</td>
</tr>
<tr>
<td>Galephar Pharmaceutical Research, Inc.</td>
<td>82 FR 23069</td>
<td>May 19, 2017.</td>
</tr>
<tr>
<td>Mallinckrodt LLC</td>
<td>82 FR 23071</td>
<td>May 19, 2017.</td>
</tr>
<tr>
<td>Cerilliant Corporation</td>
<td>82 FR 25353</td>
<td>June 1, 2017.</td>
</tr>
</tbody>
</table>

The DEA has considered the factors in 21 U.S.C. 823, 952(a) and 958(a) and determined that the registration of the listed registrants to import the applicable basic classes of schedule I or II controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated each company’s maintenance of effective controls against diversion by inspecting and testing each company’s physical security systems, verifying each company’s compliance with state and local laws, and reviewing each company’s background and history.

Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the DEA has granted a registration as an importer for schedule I or II controlled substances to the above listed persons.


Demetra Ashley,

Acting Assistant Administrator.

[FR Doc. 2017–16677 Filed 8–7–17; 8:45 am]

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Leila A. Frickey, M.D.; Decision and Order

On February 28, 2017, the Assistant Administrator, Diversion Control Division, Drug Enforcement Administration (DEA), issued an Order to Show Cause to Leila A. Frickey, M.D. (Registrant), of New Orleans, Louisiana. The Show Cause Order proposed the revocation of Registrant’s Certificate of Registration, the denial of any applications to renew or modify her registration, and the denial of any applications for any other DEA registration on the ground that she lacks “state authority to handle controlled substances” in Louisiana, the State in which she is registered with the DEA. Order to Show Cause, at 1 (citing 21 U.S.C. 824(a)(3)).

With respect to the Agency’s jurisdiction, the Show Cause Order alleged that Registrant is registered as a practitioner in schedules II through V pursuant to DEA Certificate of Registration FR docket 1574, at the address of 3312 South I–10 Service Road, Metairie, Louisiana. Id. The Order also alleged that this registration does not expire until September 30, 2017. Id.

As substantive grounds for the proceeding, the Show Cause Order alleged that on May 6, 2016, the Louisiana State Board of Medical Examiners issued a “Notice of Summary Suspension of Medical License, summarily suspending [Registrant’s] medical license.” 1 Id. at 1. As a result, the Order alleged that Registrant is “currently without authority to practice medicine or handle controlled substances in . . . Louisiana, the [S]tate in which [she is] registered with the DEA.” Id. at 2. Thus, based on her “lack of authority to [dispense] controlled substances in . . . Louisiana,” the Order asserted that “DEA must revoke” her

1 The Show Cause Order also alleges that “on July 25, 2016, the Louisiana Board of Pharmacy issued a Notice of Suspension, suspending [Registrant’s] Louisiana CDS license, number CDS.024813–MD, effective May 6, 2016.” Id. at 1–2. Although those exact facts are not reflected in the record, the record does show that on November 16, 2016, the Louisiana State Board of Pharmacy issued an Order that Registrant’s “LOUISIANA CONTROLLED SUBSTANCE LICENSE NO. 024813 is hereby indefinitely suspended in accordance with the suspension of her medical license by the Louisiana State Board of Medical Examiners on May 6, 2016.” See Government Exhibit (GX) 4, at 1.